Bile Acids as Hormones: The FXR-FGF15/19 Pathway

Identification of a nuclear receptor for bile acids

Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865

Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis

Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819

Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR

Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636

A G Protein-coupled Receptor Responsive to Bile Acids

Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628

Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors

Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,425

Identification of a nuclear receptor that is activated by farnesol metabolites

Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210

Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism

Huang, F., Zheng, X., Ma, X., Jiang, R., Zhou, W., Zhou, S., Zhang, Y., Lei, S., Wang, S., Kuang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12896-x · Cited by 799

Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases

Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745

The gut–liver axis and gut microbiota in health and liver disease

Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737

Diversification of host bile acids by members of the gut microbiota

Winston, J. A., & Theriot, C. M. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1674124 · Cited by 597

Bile acid metabolism and signaling, the microbiota, and metabolic disease

Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 529

NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425

Bile acids as modulators of gut microbiota composition and function

Larabi, A. B., Masson, H. L. P., & Bäumler, A. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172671 · Cited by 443

An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease

Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 382

Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury

Roth, K., Yang, Z., Agarwal, M., Liu, W. J., Peng, Z., Long, Z., Birbeck, J. A., Westrick, J. A., Liu, W., & Petriello, M. C. (2021) · Environment International · doi:10.1016/j.envint.2021.106843 · Cited by 322

Emerging roles of bile acids in mucosal immunity and inflammation

Chen, M. L., Takeda, K., & Sundrud, M. S. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0162-4 · Cited by 305

Bile acid signaling pathways from the enterohepatic circulation to the central nervous system

Mertens, K. L., Kalsbeek, A., Soeters, M. R., & Eggink, H. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00617 · Cited by 287

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281

Feeding gut microbes to nourish the brain: unravelling the diet–microbiota–gut–brain axis

Schneider, E., O’Riordan, K. J., Clarke, G. A., & Cryan, J. F. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01108-6 · Cited by 317

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280

Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease

Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269

Dietary fat, bile acid metabolism and colorectal cancer

Ocvirk, S., & O’Keefe, S. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.003 · Cited by 266

Natural history of metabolic dysfunction-associated steatotic liver disease.

Lekakis, V., & Papatheodoridis, G. (2023) · European journal of internal medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 222

Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance

Preidis, G. A., Kim, K. H., & Moore, D. D. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88893 · Cited by 203

Molecular basis of bile acid-FXR-FGF15/19 signaling axis

Katafuchi, T., & Makishima, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116046 · Cited by 193

FXR agonists in NASH treatment

Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 200

Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders

Rastelli, M., Knauf, C., & Cani, P. D. (2018) · Obesity · doi:10.1002/oby.22175 · Cited by 191

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial

Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187

Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death

Tang, S.-P., Mao, X., Chen, Y., Yan, L., Ye, L., & Li, S.-W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870239 · Cited by 194

Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform

Kozuka, K., He, Y., Koo-McCoy, S., Kumaraswamy, P., Nie, B., Shaw, K., Chan, P., Leadbetter, M., He, L., Lewis, J. G., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.013 · Cited by 179

Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease

Yan, C., Hu, W., Tu, J., Li, J., Liang, Q., & Han, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04166-8 · Cited by 195

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice

Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 148

The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144

Metabolic Targets in Nonalcoholic Fatty Liver Disease

Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 145

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

de Boer, J. F., Schonewille, M., Boesjes, M., Wolters, H., Bloks, V. W., Bos, T., van Dijk, T. H., Jurdzinski, A., Boverhof, R., Wolters, J. C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.037 · Cited by 142

Bile acid receptors in the biliary tree: TGR5 in physiology and disease

Deutschmann, K., Reich, M., Klindt, C., Dröge, C., Spomer, L., Häussinger, D., & Keitel, V. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.021 · Cited by 141

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC

Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000131 · Cited by 127

The Gut–Liver Axis in the Control of Energy Metabolism and Food Intake in Animals

Ringseis, R., Geßner, D. K., & Eder, K. (2019) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083852 · Cited by 129

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Mayo, M. J., Wigg, A. J., Leggett, B. A., Arnold, H., Thompson, A. J., Weltman, M., Carey, E. J., Muir, A. J., Ling, L., Rossi, S. J., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1209 · Cited by 125

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123

Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues

Mu, W., Cheng, X., Liu, Y., Lv, Q., Gao-lin, L., Zhang, J.-G., & Li, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01566 · Cited by 127

Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids

Liu, C., Du, M., Xie, L., Wang, W.-Z., Chen, B., Yun, C., Sun, X., Luo, X., Jiang, Y., Wang, K., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01570-0 · Cited by 129

Bile acids as inflammatory mediators and modulators of intestinal permeability

Calzadilla, N., Comiskey, S., Dudeja, P. K., Saksena, S., Gill, R. K., & Alrefai, W. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021924 · Cited by 123

Roles of bile acids signaling in neuromodulation under physiological and pathological conditions

Chen, X., Huang, X., Wang, D., Yu, D., Hou, S., Cui, H., & Song, L. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01053-z · Cited by 128

Current and potential treatments for primary biliary cholangitis

Shah, R. A., & Kowdley, K. V. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30343-7 · Cited by 117

Gut-liver axis signaling in portal hypertension

Simbrunner, B., Mandorfer, M., Trauner, M., & Reiberger, T. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i39.5897 · Cited by 113

Molecular tuning of farnesoid X receptor partial agonism

Merk, D., Sreeramulu, S., Kudlinzki, D., Saxena, K., Linhard, V. L., Gande, S. L., Hiller, F., Lamers, C., Nilsson, E., Aagaard, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10853-2 · Cited by 111

Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies

Dana, J., Debray, D., Bèaufrere, A., Hillaire, S., Fabrè, M., Reinhold, C., Baumert, T. F., Berteloot, L., & Vilgrain, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.042 · Cited by 109

Two apples a day lower serum cholesterol and improve cardiometabolic biomarkers in mildly hypercholesterolemic adults: a randomized, controlled, crossover trial

Koutsos, A., Riccadonna, S., Ulaszewska, M., Franceschi, P., Trôst, K., Galvin, A., Braune, T., Fava, F., Perenzoni, D., Mattivi, F., et al. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz282 · Cited by 117

Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids

Lü, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.003 · Cited by 106

Role of TGR5 (GPBAR1) in Liver Disease

Häussinger, D., & Keitel, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1669940 · Cited by 106

FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis

Ji, S., Liu, Q., Zhang, S., Chen, Q., Wang, C., Zhang, W., Chen, X., Li, Y., Nian, C., Li, J., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2018.12.021 · Cited by 106

Depletion of gut microbiota induces skeletal muscle atrophy by FXR-FGF15/19 signalling

Qiu, Y., Yu, J., Li, Y., Yang, F., Yu, H., Xue, M., Zhang, F., Jiang, X., Ji, X., & Bao, Z. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1900593 · Cited by 112

The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice

Sasaki, T., Kuboyama, A., Mita, M., Murata, S., Shimizu, M., Inoue, J., Mori, K., & Sato, R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002733 · Cited by 109

Targeting FXR in Cholestasis

Keitel, V., Dröge, C., & Häussinger, D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_231 · Cited by 106

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15

Zhou, M., Luo, J., Chen, M., Yang, H., Learned, R. M., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.027 · Cited by 102

The hypothalamus for whole-body physiology: from metabolism to aging

Liu, T., Xu, Y., Yi, C., Tong, Q., & Cai, D. (2021) · Protein & Cell · doi:10.1007/s13238-021-00834-x · Cited by 109

Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease

Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95

Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease

Gonzalez, F. J., Jiang, C., Xie, C., & Patterson, A. D. (2017) · Digestive Diseases · doi:10.1159/000450908 · Cited by 96

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human

Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 97

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology · doi:10.1002/hep.31523 · Cited by 88

Organoids to Study Intestinal Nutrient Transport, Drug Uptake and Metabolism – Update to the Human Model and Expansion of Applications

Zietek, T., Giesbertz, P., Ewers, M., Reichart, F., Weinmüller, M., Urbauer, E., Haller, D., Demir, İ. E., Ceyhan, G. O., Kessler, H., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.577656 · Cited by 92

Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism

Xu, Y., Li, Y., Jadhav, K. S., Pan, X., Zhu, Y., Hu, S., Chen, S., Chen, L., Tang, Y., Wang, H. H., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00331-1 · Cited by 91

A gut–brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus

Liu, S., Marcelin, G., Blouet, C., Jeong, J. H., Jo, Y., Schwartz, G. J., & Chua, S. C. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.12.003 · Cited by 89

Bile acids and gestation

McIlvride, S., Dixon, P. H., & Williamson, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.05.003 · Cited by 90

Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress

Song, L., Hou, Y., Xu, D., Dai, X., Luo, J., Liu, Y., Huang, Z., Yang, M., Chen, J., Hu, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.008 · Cited by 91

Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes

Calderón, G., MCRAE, A. N., Rievaj, J., Davis, J. A., Zandvakili, I., Nord, S. L., Burton, D. B., Roberts, G. P., Reimann, F. M., Gedulin, B. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102759 · Cited by 83

The interrelationship between bile acid and vitamin A homeostasis

Saeed, A., Hoekstra, M., Hoeke, M. O., Heegsma, J., & Faber, K. N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.01.007 · Cited by 85

Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A

Kim, Y.-C., Seok, S., Zhang, Y., Ma, J., Kong, B., Guo, G. L., Kemper, B., & Kemper, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19803-9 · Cited by 73

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

Sanyal, A. J., Ling, L., Beuers, U. H., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Hirschfield, G. M. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100255 · Cited by 80

Next Generation Microbiome Research: Identification of Keystone Species in the Metabolic Regulation of Host-Gut Microbiota Interplay

Tudela, H., Claus, S. P., & Saleh, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.719072 · Cited by 81

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 83

β-Klotho gene variation is associated with liver damage in children with NAFLD

Dongiovanni, P., Crudele, A., Panera, N., Romito, I., Meroni, M., Stefanis, C. D., Palma, A., Comparcola, D., Fracanzani, A. L., Miele, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.011 · Cited by 78

Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion

Wu, L., Zhou, J., Zhou, A., Lei, Y., Tang, L., Hu, S., Wang, S., Xu, X., Chen, Q., Tu, D., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2390176 · Cited by 83

Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis

Byun, S., Kim, D.-H., Ryerson, D., Kim, Y., Sun, H., Kong, B., Yau, P. M., Guo, G. L., Xu, H. E., KEMPER, B. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04697-5 · Cited by 76

Dietary Fiber from Oat and Rye Brans Ameliorate Western Diet–Induced Body Weight Gain and Hepatic Inflammation by the Modulation of Short‐Chain Fatty Acids, Bile Acids, and Tryptophan Metabolism

Kundi, Z. M., Lee, J. C., Pihlajamäki, J., Chan, C. B., Leung, K. S., So, S. S. Y., Nordlund, E., Kolehmainen, M., & El-Nezami, H. S. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900580 · Cited by 77

A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling

Shulpekova, Y. O., Shirokova, E. N., Жаркова, М. С., Tkachenko, P. E., Тихонов, И. Н., Stepanov, A. A., Sinitsyna, A. A., Izotov, A., Butkova, T. V., Shulpekova, N. V., et al. (2022) · Molecules · doi:10.3390/molecules27061983 · Cited by 77

Role of the microbiota–gut–heart axis between bile acids and cardiovascular disease

Zhang, Z., Lv, T., Wang, X., Wu, M., Zhang, R., Yang, X., Fu, Y., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116567 · Cited by 79

Novel and emerging therapies for cholestatic liver diseases

Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 74

Regulation of bile acid receptor activity

Wan, Y. Y., & Sheng, L. (2018) · Liver Research · doi:10.1016/j.livres.2018.09.008 · Cited by 75

Molecular Regulation of Bile Acid Homeostasis

Choudhuri, S., & Klaassen, C. D. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000643 · Cited by 79

Dynamics of the enterohepatic circulation of bile acids in healthy humans

Stellaard, F., & Lütjohann, D. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2020 · Cited by 74

Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH

Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66

Bile acids and cardiovascular function in cirrhosis

Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 70

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer

Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 67

FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis

DePaoli, A. M., Zhou, M., Kaplan, D. D., Hunt, S. C., Adams, T. D., Learned, R. M., Tian, H., & Ling, L. (2019) · Diabetes · doi:10.2337/db18-1305 · Cited by 65

Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids

Woolbright, B. L., & Jaeschke, H. (2019) · Gene Expression · doi:10.3727/105221619x15614873062730 · Cited by 73

Complex interaction between circadian rhythm and diet on bile acid homeostasis in male rats

Eggink, H. M., Oosterman, J. E., de Goede, P., de Vries, E. M., Foppen, E., Koehorst, M., Groen, A. K., Boelen, A., Romijn, J. A., la Fleur, S. E., et al. (2017) · Chronobiology International · doi:10.1080/07420528.2017.1363226 · Cited by 68

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0187 · Cited by 64

Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application

Struik, D., Dommerholt, M. B., & Jonker, J. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000599 · Cited by 61

New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide–Derived Drugs

Gether, I. M., Nexøe-Larsen, C., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01008 · Cited by 56

PL-S2, a homogeneous polysaccharide from Radix Puerariae lobatae, attenuates hyperlipidemia via farnesoid X receptor (FXR) pathway-modulated bile acid metabolism

Rao, Y., Wen, Q., Liu, R., He, M., Jiang, Z., Qian, K., Zhou, C., Li, J., Du, H., Ouyang, H., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.029 · Cited by 60

The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease

Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 61

Decoding FGF/FGFR Signaling: Insights into Biological Functions and Disease Relevance

Edirisinghe, O., Ternier, G., Alraawi, Z., & Kumar, T. K. S. (2024) · Biomolecules · doi:10.3390/biom14121622 · Cited by 60

RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism

Tarling, E. J., Clifford, B. L., Cheng, J., Morand, P., Cheng, A., Lester, E., Sallam, T., Turner, M., & Vallim, T. Q. D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94029 · Cited by 59

AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle

Kim, Y., Seok, S., Byun, S., Kong, B., Zhang, Y., Guo, G. L., Xie, W., Ma, J., KEMPER, B. W., & Kemper, J. K. (2018) · Nature Communications · doi:10.1038/s41467-018-03060-y · Cited by 59

The pathogenesis, models and therapeutic advances of primary biliary cholangitis

Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111754 · Cited by 59

Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?

Mayo, M. J. (2022) · Hepatology · doi:10.1002/hep.32405 · Cited by 61

The therapeutic landscape of hepatocellular carcinoma

Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 61

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics

Park, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 60

Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease

Lemons, J. M. S., Conrad, M. A., Tanes, C., Chen, J., Friedman, E. S., Roggiani, M., Curry, D., Chau, L., Hecht, A. L., Harling, L. C., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.005 · Cited by 60

GATA4 Is Sufficient to Establish Jejunal Versus Ileal Identity in the Small Intestine

Thompson, C. A., Wojta, K. J., Pulakanti, K., Rao, S., Dawson, P. A., & Battle, M. A. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.12.009 · Cited by 56

Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches

Galoosian, A., Hanlon, C. L., Zhang, J., Holt, E. W., & Yimam, K. K. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00049 · Cited by 58

Management of metabolic-associated fatty liver disease: The diabetology perspective

Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54

Newer variants of progressive familial intrahepatic cholestasis

Vinayagamoorthy, V., Srivastava, A., & Sarma, M. S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.2024 · Cited by 54

The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling

Wang, L. X., Frey, M. R., & Kohli, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.799648 · Cited by 42

Molecular basis of bile acid-FXR-FGF15/19 signaling axis

Katafuchi, T., & Makishima, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116046 · Cited by 193

Endocrine Actions of Bile Acids Via Nuclear Receptors and FGFs

Inagaki, T., Choi, M., Mangelsdorf, D. J., & Kliewer, S. A. (2007) · The FASEB Journal · doi:10.1096/fasebj.21.5.a147-a

Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling

Ciaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 76

The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism

Cariello, M., Piglionica, M., Gadaleta, R. M., & Moschetta, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_235 · Cited by 22